BREA, Calif., May 17, 2022 /PRNewswire/ — Envista Holdings Corporation (NYSE: NVST) (“Envista”) announced today that it has entered into a definitive agreement to acquire Osteogenics Biomedical Inc, Allotech LLC and OBI Biologics, Inc (together “Osteogenics”). The transaction is subject to customary regulatory approvals and is expected to close in the third quarter.
Osteogenics is a leader in the development of innovative regenerative solutions for periodontists, oral and maxillofacial surgeons and clinicians involved in implant dentistry around the world. Mainly sold under the CytoplastMT brand name, Osteogenics offers a complete line of bone grafting products. Bone grafting and regenerative therapies are often a critical step in implant tooth replacements. By improving bone stability, regenerative solutions enable better clinical outcomes for more patients.
CEO of Envista Amir Aghdaei said, “Increasing our capabilities in regenerative solutions is consistent with our intention to digitize, personalize and democratize oral care. Osteogenics is a recognized pioneer in membrane technologies used in dental bone grafting procedures. It is a trusted brand that has proven itself. of growth. We are delighted to welcome the Osteogenics team to Envista.
The transaction is not subject to a financing condition or shareholder vote.
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr, united by a common goal: to partner with professionals to improve lives. Envista helps its customers provide the best possible patient care through leading dental consumables, solutions, technologies and services. Our comprehensive portfolio, including dental implants and treatment options, orthodontics and digital imaging technologies, covers a wide range of dentists’ clinical needs for diagnosing, treating and preventing dental conditions as well as improving aesthetics. human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced management team and a strong culture built on continuous improvement, commitment to innovation and a deep customer focus, Envista is well equipped to meet end-to-end needs. needs of dental professionals around the world. Envista is one of the world’s largest dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.
Certain statements contained in this press release are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on such forward-looking statements. These factors include, among others, the impact of the COVID-19 pandemic, including new variants of the virus, the pace of recovery in the markets in which we operate, global supply chain disruptions and potential staff shortages, conditions in the United States and the global economy, the markets we serve and capital markets, the impact of our debt securities on our operations and liquidity, policy developments and uncertainties and trade regulations, contractions or growth rates and cyclicality of the markets we serve, the effect of the Osteogenics acquisition on our business relationships, results of operations, stock price or business in general, the failure to realize the expected benefits of the Osteogenics acquisition, fluctuations in our distributors’ and customers’ inventory, the loss of a key distributor, our relationships with and the perf ormance of our channel partners, competition, our ability to successfully develop and market new products and services, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including medical device and health care industry regulations), results of our clinical trials and their perceptions, penalties associated with any commercialization of our products, changes to our products that require new approvals or clearances time-to-market, our ability to respond effectively to cost reductions and other changes in the healthcare industry, our ability to identify and successfully complete appropriate acquisitions and strategic investments, our ability to integrate businesses that we acquire and realize the anticipated benefits of this s acquisitions, contingent liabilities related to acquisitions, investments and divestitures, security breaches or other disruptions to our information technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our structuring activities on our ability to grow, exchange rate risks, changes in tax laws applicable to multinational enterprises, litigation and other contingent liabilities, including intellectual property and environmental, health and security risks, product, service or software defect risks, product manufacturing risks, raw material costs and surcharges, our ability to adjust purchasing and manufacturing capacity to reflect prevailing conditions market, reliance on single or limited sources of supply, the impact of regulation on demand for our products and services, labor issues, international economic, political, legal, compliance and trade issues, and disruptions related to war, terrorism, climate change, general civil unrest and protests, man-made and natural disasters, public health concerns and other events. Additional information regarding factors that could cause actual results to differ materially from these forward-looking statements is available in our filings with the SEC, including our Annual Report on Form 10-K for Fiscal 2021 and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement, whether result of new information, future events and developments or otherwise.
Envista Holdings Corporation
200 S. Kraemer Boulevard, Building E
Brea, California 92821
Telephone: (714) 817-7000
Fax: (714) 817-5450
Show original content to download multimedia:https://www.prnewswire.com/news-releases/envista-to-acquire-osteogenics-biomedical-business-301549633.html
SOURCEEnvista Holdings Corporation